pubmed.ncbi.nlm.nih.gov

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB - PubMed

  • ️Wed Jan 01 2003

. 2003 Aug 14;424(6950):797-801.

doi: 10.1038/nature01811.

Affiliations

Free article

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB

Thijn R Brummelkamp et al. Nature. 2003.

Free article

Abstract

Protein modification by the conjugation of ubiquitin moieties--ubiquitination--plays a major part in many biological processes, including cell cycle and apoptosis. The enzymes that mediate ubiquitin-conjugation have been well-studied, but much less is known about the ubiquitin-specific proteases that mediate de-ubiquitination of cellular substrates. To study this gene family, we designed a collection of RNA interference vectors to suppress 50 human de-ubiquitinating enzymes, and used these vectors to identify de-ubiquitinating enzymes in cancer-relevant pathways. We report here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD), having no known function, enhances activation of the transcription factor NF-kappaB. We show that CYLD binds to the NEMO (also known as IKKgamma) component of the IkappaB kinase (IKK) complex, and appears to regulate its activity through de-ubiquitination of TRAF2, as TRAF2 ubiquitination can be modulated by CYLD. Inhibition of CYLD increases resistance to apoptosis, suggesting a mechanism through which loss of CYLD contributes to oncogenesis. We show that this effect can be relieved by aspirin derivatives that inhibit NF-kappaB activity, which suggests a therapeutic intervention strategy to restore growth control in patients suffering from familial cylindromatosis.

PubMed Disclaimer

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances